Table 3.
Summary of clinical symptoms and laboratory tests of 34 patients.
| Parameter | Value | |
|---|---|---|
| Symptoms and signs (33)a | asymptomatic neuroglycopenic symptoms |
1 (3.0%) 32 (97.0%) |
| consciousness disturbance seizure sweating confusion asthenia tremor dizziness coma lethargic pale skin and mucous membranes nausea deliration other rare symptoms: dyspnea, slurred speech, numbness, incoherence, inability to speak, disorienting, nonresponsive, fall, loss of muscle tone, hunger, hypothermia, dehydration, visual hallucinations, spoke nonsense words, displayed dancing arms, headaches |
10 (30.3%) 8 (24.2%) 6 (18.2%) 5 (15.2%) 4 (12.1%) 3 (9.1%) 3 (9.1%) 3 (9.1%) 3 (9.1%) 2 (6.1%) 2 (6.1%) 2 (6.1%) 1 (3.0%) |
|
| Serum glucose (mg/dL) | 28.8 (12,60) b | |
| Insulin (μU/mL) (19)a | 31.8 (3,115.3) b | |
| elevated normal |
15 (78.9%) 4 (21.1%) |
|
| C-peptide (ng/mL) (13)a | elevated | 13 (100%) 7.7(2.2,20) b |
| Renal (33) a | normal renal impairment* |
8 (24.2%) 25 (75.8%) |
| Liver (22)a | hepatitis normal |
2 (9.1%) 20 (90.1%) |
* Renal impairment were categorized according to their estimated creatinine clearance at screening: normal renal function (≥ 90 mL/min/1.73 m2), mild impairment (60–89 mL/min/1.73 m2), moderate impairment (30–59 mL/min/1.73 m2) and severe impairment (15–29 mL/min/1.73 m2).
a Represents the number of patients out of 34 in whom information regarding this particular parameter was provided.
b Median (minimum-maximum).